The Rheumatology Research Foundation’s largest fundraising campaign, Journey to Cure, has surpassed its $60 million fundraising, raising a grand total of $61,430,466. With the support of 3,869 donors, the campaign has funded awards for more than 900 rheumatology professionals.
You Might Also Like
Explore This IssueApril 2017
Also By This Author
“The success of Journey to Cure demonstrates the commitment rheumatologists and health professionals have to impacting patient care through research and training,” says Mary Wheatley, IOM, CAE, the Foundation’s executive director. “By working together to support the future of this field, we have achieved a monumental milestone that will serve generations to come.”
In support of the Foundation’s mission to improve the health of people with rheumatic diseases, Journey to Cure was implemented in 2012 with a goal of raising $60 million over five years. By the end of 2016, the campaign had surpassed its goal by more than $1.4 million. Dollars raised during the campaign are directly invested into the Foundation’s mission objectives to recruit and train future rheumatologists and health professionals, foster innovative research ideas in rheumatology, and accelerate advancements in treatments and cures for all rheumatic diseases.
Among the awards supported by Journey to Cure were 197 education and training awards that build the rheumatology workforce and help decrease patient wait times, 102 career development awards that encourage investigators to study rheumatic diseases, 523 student awards that recruit and train future rheumatology professionals and 87 Innovative Research Awards for investigators studying the underlying causes and potential treatments of rheumatic diseases.
Alexis Ogdie, MD, MSCE, is one of several rheumatology professionals who received Foundation funding during Journey to Cure. “The ultimate goal of rheumatology research is really to support patients, to improve the treatment and options for patients and to improve long-term outcomes. Supporting rheumatologists through their career in order to launch their research career and really sustain it is incredibly important for those things to be accomplished,” Dr. Ogdie said.
In addition to advancing careers and funding research for investigators, Journey to Cure inspired an unprecedented $10,627,579 in donations from 2,604 donors from the rheumatology community, including ACR and ARHP members. A $5 million donation from the ACR inspired Leadership-level commitments from two ACR members, which enabled the Foundation to expand its award offerings to better fill needs within rheumatology.
The Tobé and Stephen E. Malawista, MD, Endowment in Academic Rheumatology became the largest named endowment at the Foundation. It was established by a past president and member of the ACR, and provides a permanent source of support for early career investigators to conduct basic science research and develop their careers.
Likewise, the Norman B. Gaylis, MD, Research Award for Rheumatologists in Community Practice was established to encourage research from physicians who are engaged in patient care.
The success of Journey to Cure would not have been possible without support from the Corporate Roundtable, which played a fundamental role. AbbVie, Amgen, Genentech and Pfizer were among the pharmaceutical industry leaders who joined the dynamic partnership in support of Journey to Cure.
“At AbbVie, we are committed to fostering innovation in rheumatology and advancing research for rheumatic diseases,” says Jim Salanty, vice president, U.S. Rheumatology, AbbVie. “It has been an honor to support the Journey to Cure campaign over the past several years and to partner with the Rheumatology Research Foundation in its mission to improve treatment options and advance care for patients living with these potentially debilitating diseases.”
Amgen Inc. has also been an integral supporter of the Foundation’s awards and grants program. “As a long-time partner of the Rheumatology Research Foundation and supporter of its awards and grants program, we are thrilled to see the success of the Journey to Cure campaign,” says Daniel Billen, vice president and general manager, Inflammation and Nephrology at Amgen. “Recruiting and training future rheumatologists is an important step in helping advance the research and treatment outcomes for all rheumatic diseases, and we are proud to see the rheumatology community come together to exceed the fundraising goal for this campaign.”
“At Pfizer Inc., we are enormously proud of the success of Journey to Cure, which acknowledges the need for research and dedication to the field in order to help drive improvements in patient outcomes,” says Andrew Koenig, DO, FACR, Inflammation & Immunology Group Lead North America Medical Affairs, Pfizer Inc. “Pfizer believes in putting patients first, which is why we’re honored to support an organization that recognizes that when rheumatologists are fully engaged in their profession they can better help people with rheumatic conditions live healthier lives.”
For those affected by rheumatic diseases, Journey to Cure offers hope for better health and a brighter future. Steve and Debbie Russell, whose daughter Courtney suffered with symptoms for nine months before she was diagnosed with systemic juvenile idiopathic arthritis, explain their support of the Foundation. “My appreciation and admiration for the Foundation have done nothing but skyrocket, and I give my eternal thanks to the doctors, researchers and investigators who truly dedicate their lives to making a difference for the people who suffer from these diseases,” Steve Russell says.